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Summary.-The relative efficiency of active nonspecific or specific immunotherapy
of developing methylcholanthrene induced fibrosarcomata with C. parvum was
compared. For nonspecific immunotherapy, mice were challenged with tumour
cells s.c. or i.v., and 2 days later injected i.v. with dilutions of C. parvum. The only
significant eflect was a retardation of s.c. tumour growth by the highest concentration
of C. parvum (350,ug). However, active specific immunotherapy, using mixtures of
C. parvum and irradiated or living tumour cells in the footpads, suppressed tumour
growth when given at 2 or 6, but not 10, days after tumour challenge. Successful
therapy required: sufficient tumour cells (35 x 104); an optimal dose of C. parvum
(5-120,ug, increasing with the number of tumour cells); an intact T cell system; the
same tumour cells for challenge and treatment. The specificity was confirmed in a
protection system in which treatment was given 7 days before tumour challenge.
No protective immunity could be achieved with mixtures of C. parvum and foetal
cells. Thus in this system C. parvum potentiates protective immunity only to the
tumour unique TSTA.
ACTIVE specific immunotherapy of MATERIALS AND METHODS
rodent tumours with irradiated tumour Mice.-Male CBAT6T6 mice aged 8-12
cells canbeaccomplishedwhenthetumours wz%eeks, bred in this department, were used.
are small (Haddow and Alexander, 1964), C. parvum-A killed saline suspension
and in some cases therapy is improved if (Wellcome strain CN6134, batch PX374),
Bacillus Calmette-Guerin is given as well prepared by the method of Adlam and
(Mathe, Pouillart and Lapeyraque, 1969; Scott (1973), was provided by Wellcome
Parr, 1972). Corynebacterium parvum is Reagents Ltd, Beckenham, Kent.
an adjuvant in non-tumour s stems Tumours. Tumours appeared in male an adjuvant in non-tumour systems CBAT6T6 mice 4-5 months after the intra-
(reviewed by Howard, Scott and Christie, muscular injection in the thigh of 0.1 ml of
1973) and there is evidence that it can, methylcholanthrene (5 mg/ml in olive oil,
when used in combination with irradiated kindly provided by Dr J. A. Wright of the
tumour cells, potentiate the immune Imperial Cancer Research Fund, London),
response to tumour-specific transplan- and were maintained by transplantation in
tation antigens (TSTA) (Proctor, Ruden- male CBAT6T6 mice and in tissue culture.
stam and Alexander, 1973; Scott, 1974a). Three independently induced tumours,
This paper describes the use of '. parvum M2, M3 and M4, were used in these experi- This paper describes the use Of C. parvu ''1ments.
and irradiated tumour cells for the Tum.our cell suspensions-Cells were
immunotherapy ofmethyleholanthrene in- obtained directly from tumours by mincing
duced fibrosarcomata (MC fibrosarcomata) small fragments of non-necrotic tumour
of CBA mice. Some factors controlling tissue in PBS, pushing the fragments through
the success of therapy are analysed. a sieve, allowing the debris to settle and552 R. BOMFORD
washing the cells in PBS. Viability was tumour growth by the highest dose of
20-30% by trypan blue exclusion. C. parvum (350 ,tg).
Tissue culture cells werekeptinDulbecco's
modification (containing 4 times the usual Therapyusing C. parvum irradiated tumour
amount of amino acids) of Eagle's medium cell mixtures: effect of varying doses of C. with 10% heat inactivated foetal calf serum andirrdtcells (Wellcome Reagents Ltd). They were parvum andirradiatedcells
brought into suspension with 0-1% trypsin Mice were injected s.c. with 104 tissue
in 0.05% versene. cultured M4 cells and treated 2 days later
Foetal calf suspensions.-10-14 day old with graded doses of irradiated M4 cells
foetuses were minced, the fragments stirred and C. parvum. Table II shows that
in 0.1% trypsin in PBS for 5-10 mm at 370C, dilutions of C. parvum or of irradiated
the fluid decanted, calf serum added to 10% tumour cells given alone did not suppress and spun at 1000 g for 5 mm. The cell pellet . .
r was resuspended in PBS-10% FCS. Viability or significantly retard tumour growth.
was >90%. Mixtures containing the smallest number
Irradiation of cells.-Cells were exposed (5X103) of M4 cells were ineffective but
to 10,000 rad from a 60Co source. with 5 x 104 M4cellstherapywassuccessful
Tumour challenge and therapy.-0-1 ml at the lower doses of C. parvum (1.4 and
(for dorsal s.c. challenge) or 0-2 ml (for i.v. 5.5 Itg) but not at the higher doses
challenge) of tumour derived cells in PBS or (22 and 88 ,ug), although with 22 ,tg of
tissue culture cells in medium were injected. C. parvumthere was asignificantreduction
Fortherapy, 0-05 ml of dilutions ofC. parvum of tumour weight (the only one in this and/or tumour cells in saline were injected experiment). When the number of M4 into both footpads. ce raiedto When th erapy Mice challenged s.c. were palpated weekly cellswasraisedto 5 x 105, complete therapy
for tumours until control tumours started to was achieved with 22 ,ug of C. parvum,
ulcerate and were thenkilled andthe tumours and partial therapy (only 1/5 mice with
weighed. Mice challenged i.v. were scored tumours) at the other dilutions. The
for survival up to 80 days, the remaining mice mice which remained tumour-free at
then being killed. Lungs were examined for 6 weeks had not developed palpable
tumours by the method of Wexler (1966). tumours earlier.
T cell depleted mice.-Mice were thymecto- Since in this experiment tissue culture
mized, irradiated (850 rad) and reconstituted M4 cells were used both for tumour chal-
with 2 > 106 bone marrow cells followino' the
method of Davies et al. (1966). lenge and therapy, the possibility that
Statistics.-Statistical manipulation ofthe tumour suppression could be due to
data was carried out by Mr D. Field, Well- immunity to tissue culture constituents
come Research Laboratories. The logl0geo- was excluded by repeating part of the
metric means of tumour weights were com- experiment, using 106 irradiated tumour
pared using a pooled variance estimate from derived M4 cells for therapy. Five/5 mice
all groups. The arithmetic means ofsurvival developed tumours in the untreated con-
times were compared by Student's t test. trols, and in the groups given M4 cells or
Significance ~ ~ ~ ~ trls ansP<0 the grusgvn clso Significance was P<0-05. C. parvum dilutions alone. Therapy with
mixtures, as before, was successful only
with lower doses of C. parvum: 350 ,ug,
RESULTS 5/5; 88 /ag, 4/5; 22 jug, 1/5; 5.5 jag, 0/5.
Effect of C. parvum injected alone i.v.
against tumour challenge Efficacy of delayed therapy
Mice were injected i.v. with 2 x 105, Mice were injected s.c. with 104 tissue
or s.c. with 104 tissue culture M4 cells, and culture M4 cells 6 or 10 days before treat-
2 days later injected i.v. with dilutions of ment with 5 x 105 irradiated tissue culture
C. parvum. Table I shows that the only M4 cells, 22 jag C. parvum, or mixtures.
significant effect was a retardation of s.c. TableIIIshowsthattherapywassuccessfulIMMUNOTHERAPY OF MOUSE TUMOURS 553
TABLE I.-The Effect of i.v. Treatment with C. parvum 2 Days after s.c.
or i.v. Challenge with M4 Cells
s.c. challenge (104 cells) i.v. challenge (2 x 105 cells)
, A , A
Amount Proportions mice Tumour weights Proportions mice Survival time
C. parvum with tumours at (mg, loglo geometric dead at 80 days (davs, arithmetic
(,ug) 6 weeks mean ± s.e.) mean ± s.e.)
None 6/7 2-36+0-42 6/7 49-6±4-9
350 5/5 1-36±0-29* 6/7 55-7±3-2
88 5/5 1-89+0-36 5/7 51-1+5-3
22 5/5 2-26+0- 18 7/7 55- 33- 7
5-5 5/5 2-29±0-11 7/7 50-1±5-5
1-4 5/5 2-49±0-08 5/7 43-7±4-1
* P<0*05, compared with untreated controls.
TABLE II.-Footpad Treatment of Mice with C. parvum, Irradiated M4 Cells
or Mixtures, 2 Days after s. c. Challenge with 104 M4 Cells. The Effect of
varying the Dose of C. parvum and Number ofTumour Cells
Proportion of mice with tumours, and tumour weights (mg, log10 geometric mean ± s.e.)
Amount of C. parvum (,zg)
No.of irradiated , I
M4 cells None 1-4 5-5 22 88
None 4/5 5/5 5/5 4/5 5/5
2-21±0-15 1.80±0-11 1-39±0-30 1-7440-20 1-88±0-11
5x 103 5/5 5/5 5/5 4/5 4/5
2-22±0 19 2-02±0-21 1-85±0 11 2-23±0-30 2-02±0-44
5 x104 5/5 0/5 0/5 5/5 5/5
1-54±0-35 0.97±0- 18* 2 02±0 17
5 x 105 5/5 1/5 1/5 0/5 1/5
2-34±0-21 1*76 2-22 2-23
* P <0 -05, compared with untreated controls.
TABLE III.-Footpad Treatment of Mice with C. parvum, Irradiated M4 cells
or Mixtures 6 or 10 Days after s.c. Challenge with 104 M4 Cells
Day 6 treatment Day 10 treatment
Expt 1 Expt 2 Expt 1
Untreated controls Not done 5/5 (2 03±0- 77) Not done
C. parvum (22 Mg) 4/5 (1-69±0-16) 5/5 (2-08±0-85 4/5 (2 45±0 79)
M4cells (5x 105) 5/5 (2-29±0-17) 5/5 (1-72±0-28) 5/5 (2-28±0-11)
C. parvum plus M4 cells 0/5 1/5 (1-53) 4/5 (1-83±0-43)
at 6 days after tumour challenge, when The effect ofT cell depletion
no convincingly palpable tumours could MicedepletedofTcellsbythymectomy,
be found. In the first experiment one irradiation and reconstitution with bone
tumour was palpable at 14 days after s.c. marrow cells (TX-IRR-BM) and irradiated
challenge, but not at Day 21; in the second reconstituted controls (IRR-BM) were
experiment all 5 tumours were palpable challenged s.c. with 104 M4 cells and
at Day 14, and 4 out of5 had disappeared treated 2 days later with 5x 105
at Day 21. irradiated tissue culture M4 cells, 5*5
Therapy 10 days after s.c. challenge, ,ug C. parvum or a mixture (Table IV).
when the tumours were already palpable, Therapy was impaired in T cell depleted
was ineffective. mice.554 R. BOMFORD
TABLE IV.-Footpad Treatment with C. parvum Irradiated Tumour Cells or
Mixtures, 2 days after s.c. Challenge with 104 M4 Cells in T Cell Depleted
(TX-IRR-BM) or Control (IRR-BM) Mice
Proportion of mice with tumours and
tumour weights (mg, log10 geometric mean ± s.e.)
IRR-BM TX-IRR-BM
Untreated controls 4/4 (1 71±0 12) 4/4 (1-75±0 37)
C. parvum (5* 5 ,g) 4/4 (2*08±0i05) 4/4 (2*16i0-09)
M4 cells (5 x 105) 4/4 (1*95i0*15) 4/4 (1*92±0*10)
C. parvum plus M4 cells 1/4 (0 70) 4/4 (1-74±0 36)
TABLE V.-The Specificity ofFootpad Therapy with C. parvum and Irradiated
Tumour Cells
Proportion of mice with tumours and
tumour weight (mg, logl0 geometric mean±s.e.)
M3 challenge M4 challenge
Untreated controls 5/5 (2-10+0 21) 4/5 (1 56+0-09)
C. parvum (22 jg) 5/5 (1-87±0-31) 2/5 (1 23±0-53)
M3 cells (5x 105) 4/5 (2-29+0-49) 3/5 (1-82±0-08)
M4 cells (5 x 105) 5/5 (2*40±0*61) 3/5 (2*09±0*37)
C. parvum plus M3 cells 0/5 3/5 (1-80± 0-12)
C. parvum plus M4 cells 4/5 (2. 17+0-31) 0/5
Challenge with independently induced M3 or M4 tumour cells and therapy 2 days later with homologous
or heterologous cells.
TABLE VI.-Specificity of the Protective Effect ofFootpad Treatment with
C. parvum and Irradiated Tumour Cells. Treatment given 7 Days before s.c.
Challenge with 104 M4 Cells
Proportion of mice with tumours and
tumour weights (mg, logl0 geometric mean i s.e.)
Cells in treatment mixture
Amount of r A A
C. parvum (jsg) None M3 M5
5/5 5/5 3/5 None 2-060- 11 2-29±0 06 1-45±022
5/5 5/5 0/5
22 1-94±0-31 1-80+0-29
5/5 5/5
5.5 2-07±0-15 2-16+0-13 Not done
5/5 5/5
1*4 1-52±0-22 2-15±0-12 Notdone
Specificity of therapy M4 or M2 cells and 2 days later injected
Mice were injected s.c. with 1-5 x 104 in the footpads with 120 ,tg of C. parvum
M4 cells or 2 x 104 M3 cells and 2 days and 106 living M2 or M4 cells. All the
later received therapy with 5 x 105 mice treated with C. parvum and homo-
irradiated tissue culture M3 or M4 cells, logous tumour cells were without lung
22 /tg C. parvum or mixtures (Table V). nodules when killed 80 days after i.v.
Homologous cells were required in therapy challenge. Treatment with mixtures
mixtures. containing heterologous cells did not pro-
The specificity of therapy was con- long survival (M4 cell challenge, mean
firmed using i.v. challenge with tumour survival time, days i s.e., untreated
cells. Mice were injected i.v. with 2 x 105 controls 49 0 j 3-6, C. parvum-M2 cellIMMUNOTHERAPY OF MOUSE TUMOURS 555
treatment 54-9 ± 4-8; M2 cell challenge, not excessive C. parvum is required,
untreated controls 35-2 ± 1 2, C. parvum- effective doses lying between 1-4 and 120
M4 cell treatment 38-6 = 1-5). ,tg, and increasing with the number of
To increase the chances of detecting a tumour cells. These dose requirements
low level of cross reactive anti-tumour are in contrast to those for therapy with
resistance, further specificity experiments i.v. C.parvum alone where onlythe highest
were performed using a protection model dose (350 ,tg) retarded tumour growth.
in which treatment preceded tumour A similar distinction in dose requirements
challenge. has previously been described for the
Mice were injected in the footpads P-185 mastocytoma growing on the foot-
with 106 irradiated tissue culture M3 or pad of C57B1 x DBA/2 mice, where
M4 cells, with dilutions of C. parvum or retardation of tumour growth could be
with mixtures, and were challenged s.c. best achieved with a high dose (700 ,tg)
7 days later with 4 x 104 viable tumour of C. parvum i.v. (Scott, 1974b), whereas
derived M3 or M4 cells. Table VI shows regressions after intralesional injections
the results ofthe M4 challenge experiment. were more frequent with lower (35 or 70
Prior treatment with M4 cells alone con- ,ug) than higher (350 ,ug) doses (Scott,
ferred partial resistance, which became 1974a). It has been suggested that higher
complete in conjunction with 22 ,ag of doses of C. parvum are ineffective for
C. parvum. Heterologous M3 cells alone intralesional therapy because the draining
or admixed with 22, 5-5 or 1-4 ,ug of C. nodes become too severely disorganized by
parvum did not generate resistance. histiocyticinfiltrationtomountanimmune
The reciprocal experiment using M3 response to tumour antigens (Scott, 1974c).
cells for s.c. challenge gave analogous However, the observation in this paper
results; only M3-C. parvum mixtures were that the upper limit for the dose of C.
protective (results not shown). parvum in mixtures increases with the
number of tumour cells suggests an
The use offoetal cells explanation based on the necessity for a
C. parvum-foetal cell mixtures were balance between C. parvum and tumour
tested in the protection model. Up to antigen.
3 x 106 lining or irradiated syngeneic An intact T cell system was required
(CBA) or allogeneic (BALB/c) 10-14 day for therapy. This, together with the
foetal cells were injected in the footpads exquisite specificity of the system,
with varying doses of C. parvum 7 days suggests that C. parvum is promoting
before s.c. challenge with M3 or M4 trells. immunity to the non-cross-reacting TSTA.
No suppression or retardation of tumour It remains to be determined whether cell
growth was achieved. mediatedorhumoralimmunityisinvolved,
but cell mediated must be favoured since it
DISCUSSION has already been shown for the P-185
The present results show that devel- mastocytoma in C57B1 x DBA/2 mice
oping MC fibrosarcomata canbeeliminated that lymph node cells, but not serum,
after treatment with mixturesofC.parvum from mice pretreated with C. parvum and
and irradiated or living tumour cells. irradiated tumour cells prevents the out-
The following factors affected the outcome growth of admixed tumour cells trans-
oftreatment. ferred to a sub-lethally irradiated recipient
Sufficient tumour cells are required (Scott, 1975).
inthe mixtures,the minimumforirradiated Although therapy given 6 days after
cells lying between 5 x 103 and 5 x 104. tumour challenge suppressed tumour
No upper limit was detected, as therapy growth, therapy at 10 days did not even
was successful with the largest number retard tumourgrowth. This suggests there
tested, 106 living cells. Sufficient but is a critical tumour size, beyond which556 R. BOMFORD
therapy must fail, due either to the log-
arithmicgrowthofthetumouroutstripping
the constant destruction of tumour cells
by the immune system or to blocking
factors.
Therapy or protective immunity
required the use of the same tumour cells
for treatment and challenge; there was
no evidence that C. parvum, as used in
this study can potentiate immunity (of a
type conferringtransplantation resistance)
to the cross-reacting foetal antigens known
to exist on mouse and rat MC-fibro-
sarcomata (Braun, 1970; Baldwin, Glaves
and Vose, 1972; Thomson and Alexander,
1973; LeMevel and Wells, 1973).
The implications of the animal experi-
mental work for the use ofC. parvum as an
immunotherapeutic agent in man have
been reviewed by Scott (1974c), but some
comments specifically related to the pre-
sent work can be made. If C. parvum
is used with irradiated tumour cells for
activespecificimmunotherapy, thenumber
of tumour cells used may not be critical,
although it would be justifiable to use the
maximum feasible so as not to fall below
the antigen threshold. Care must be
taken to avoid using excessive C. parvum.
In order to circumvent C.parvum overdose
it would be preferable to apply repeated
treatments to areas drained by different
lymph nodes. If no tumour cells are
available, active specific immunotherapy
may still be attempted by injecting
C. parvum on its own at a site where it will
stimulate a draining lymph node which is
likely to be already containing tumour
antigen. It has been shown in the P815
mastocytoma system that C. parvum and
irradiated tumour cellsinjectedatdifferent
sites can generate protective immunity,
provided that they stimulate the same
lymph node (Scott, 1975). In the light
of the specificity data presented in this
paper, it will be preferable to use irradi-
ated autochthonous tumour cells when-
ever possible unless there is good evidence
for cross-reacting antigens of a type
capable of stimulating anti-tumour
resistance.
Finally, although it has now been
demonstrated in this system and for the
P-815 mastocytoma (Scott, 1974a, b) that
i.v. treatment with C. parvum produces
a relatively weak anti-tumour effect,
this method of administering C. parvum
should not be discounted for clinical use.
Firstly, it might enable C. parvum to come
into contact with, and stimulate the
immune response to, systemically distri-
buted tumour cells at sites such as the liver
or bone marrow. Secondly, since i.v.
C. parvum produces an anti-tumoureffect
which is independent of the immune
response to TSTA (Scott, 1974c), it might
provide some resistance to tumour growth
in situations where the possibility of
active specific immunotherapy is dim-
inished either by lack of antigenicity of
the tumour or by immunological energy
of the patient.
The author thanks Mr S. Wishart for
excellent technical assistance, and Drs M.
Scott and J. Ivanyi for helpful criticism
of the manuscript.
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